Table 3 Univariate and multivariate analysis of the prognostic impact of clinicopathological variables and the clonality of driver genes

ANK1

88%

 Subclonal vs WT

4.53

1.97–10.43

 < .001

6.09

1.36–27.29

0.018

6.64

1.6–27.5

9e−3

1.78–28.84

 Clonal vs WT

0.78

0.32–1.93

0.60

0.95

0.31–2.95

0.932

0.99

0.32–3.07

0.98

0.34–3.55

ARID1A

64.9%

 Subclonal vs WT

3.68

1.49–9.07

4.6e−3

1.20

0.22–6.70

0.83

1.66

0.32–8.54

9e−3

0.45–29.3

 Clonal vs WT

0.58

0.27–1.24

0.1581

0.18

0.06–0.60

0.005

0.23

0.07–0.71

1.1e−2

0.07–0.65

SMAD2

88.8%

 Subclonal vs WT

1.14

0.28–4.63

0.85

2.90

0.37–22.46

0.31

2.07

0.28–15.5

0.48

0.96–22.80

 Clonal vs WT

2.61

1.36–4.999

0.0038

3.51

1.639–7.55

0.001

3.76

1.78–7.91

1e−3

2.03–9.93

CASP8

92.5%

 Subclonal vs WT

0

0-Inf

0.993

0

0-Inf

0.994

0

0-inf

0.995

0-inf

 Clonal vs WT

5.28

2.56–10.88

 < 1e−4

5.91

2.43–14.36

1e−4

6.33

2.63–15.23

 < 1e−3

2.82–18.82

Age

100%

 >  = 67.5 vs < 67.5

2.14

1.44–3.17

2e−04

3.25

1.99–5.32

 < 1e−4

3.04

1.89–4.89

 < .001

2.16–6.01

Sex

36.1%

 Male vs Female

1.05

0.73–1.52

0.79

0.78

0.51–1.20

0.26

–

–

–

0.41–1.02

Tumour site

48.5%

 Left vs Right

0.72

0.49–1.04

0.08

0.74

0.48–1.15

0.186

0.7

0.45–1.07

0.097

0.38–0.95

M_stage

98.2%

 M1 vs M0

3.92

2.56–5.99

 < 1e−4

2.92

1.68–5.07

1e−4

3.22

1.89–5.49

 < .001

1.82–5.59

N_stage

45.7%

 N1/N2 vs N0

2.47

1.70–3.59

 < 1e−4

0.53

0.17–1.68

0.28

–

–

–

0.49–1.90

T_stage

39.3%

T3/T4 vs T1/T2

2.46

1.28–4.72

0.006

1.76

0.72–4.34

0.22

–

–

–

1.00–10.07

TNM_stage

88.7%

 Stage 3/4 vs Stage 1/2

2.70

1.82–4.01

 < 1e−4

5.31

1.49–19.02

0.01

2.78

1.62–4.76

 < .001

2.16–12.91

MSI status

34.1%

 MSI vs MSS

0.80

0.54–1.15

0.22

0.79

0.48–1.29

0.34

–

–

–

0.38–1.06